Repligen Corp. Stock
Price
Target price
€137.40
€137.40
3.890%
5.05
3.890%
€149.03
05.08.26 / Tradegate
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Repligen Corp. Stock
Repligen Corp. dominated the market today, gaining €5.05 (3.890%).
With 20 Buy predictions and not the single Sell prediction the community is currently very high on Repligen Corp..
With a target price of 149 € there is a slightly positive potential of 8.44% for Repligen Corp. compared to the current price of 137.4 €.
So far the community has only identified positive things for Repligen Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Repligen Corp. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | 3.890% | 11.210% | 12.439% | 37.194% | -2.449% | -11.923% | -36.212% |
| Opko Health Inc. | 1.820% | -20.000% | -11.111% | 7.817% | 2.733% | -36.951% | -63.170% |
| China Traditional Chinese Medicine Co Ltd | 0.000% | 0.000% | 0.000% | -5.172% | 0.917% | -45.813% | -55.645% |
| Viatris Inc. | -0.610% | -2.053% | 5.895% | 96.854% | 44.926% | 58.612% | 29.764% |
Comments
Repligen (RGEN) was upgraded by Zacks Research from "hold" to "strong-buy".
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target raised by Wells Fargo & Company from $180.00 to $185.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its price target raised by JPMorgan Chase & Co. from $165.00 to $175.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat